74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Codexis Inc
Closed
Sector Healthcare
4.17 -2.11
Overview
Share price change
24h
Min
4.16
Max
4.24
Income | 2.1M -21M |
|---|---|
Sales | 4.9M 13M |
EPS | -0.29 |
Profit margin | -160.835 |
Employees | 174 |
EBITDA | 7M -14M |
Next Earnings | 27 Feb 2025 |
|---|
Market Cap | 344M |
|---|---|
Previous open | 6.28 |
Previous close | 4.17 |
News Sentiment
By Acuity
35%
65%
109 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Codexis Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Codexis Inc Forecast
Sentiment
By Acuity
109 / 393 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Codexis Inc
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
